Stocks
Belite Bio, IncBLTE
NASDAQHealthcareBiotechnology$164.11-3.21%
Price as of · delayed, not real-time
Focused on developing novel therapeutics for retinal degenerative diseases, this biopharmaceutical company has gained investor attention due to its promising pipeline targeting unmet medical needs. Its lead candidate, LBS-008, is in late-stage clinical trials for Stargardt disease, a rare genetic eye disorder.
Market Cap: $6.5B52W Range: $49.00 – $200.00
Congressional Interest in Belite Bio, Inc (BLTE)
No congressional trades have been disclosed for Belite Bio, Inc (BLTE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BLTE?
No congressional trades found for this stock.